The presence of SCs in NB tumors was recognized in the early 1980s [2] as a marker of favorable outcome [3], and the contribution of ECs and tumor-derived vascular endothelial cell growth factor (VEGF) to NB progression was reported in the late 1990s [4]. The gene discussed is VEGFA; the disease is neoplasm.